As previously reported, Argus downgraded Biogen (BIIB) to Hold from Buy. The company has provided guidance for 2025, noting that it expects ...

Biopharma leaders react to the forced resignation of CBER Head Peter Marks as RFK Jr.’s promised job cuts begin at the FDA; ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

An experimental treatment appears to postpone Alzheimer's symptoms in some people genetically destined to get the disease at ...

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...

A European regulatory committee rejected Eli Lilly's U.S.-approved Alzheimer's disease treatment over potentially dangerous risks of brain bleeding and swelling.

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

Pluvicto, Novartis’ blockbuster radiopharmaceutical for prostate cancer, has been greenlighted by the FDA for use earlier in ...

Esto ocurrió un año después de que aprobaran un fármaco similar, Leqembi, de la farmacéutica japonesa Eisai. Los medicamentos ...